Assess whether RWE can replace or only supplement an RCT (721c3a)

Situation

The desk packet is scientific-advice briefing book after a CRL citing manufacturing, not efficacy. CMC change-control owner in a safety team sitting on a new disproportionate signal has to name RWE can replace or Only supplement an RCT for this Pharma & Life Sciences Clinical and Evidence Strategy file.

Decision

CMC change-control owner in a safety team sitting on a new disproportionate signal must choose RWE can replace / Only supplement an RCT using scientific-advice briefing book after a CRL citing manufacturing, not efficacy.

Hypotheses to test

• The population in scientific-advice briefing book is the one a CRL citing manufacturing, not efficacy named, so RWE can replace follows for this Clinical and Evidence Strategy file.
• The population in scientific-advice briefing book is adjacent only to a CRL citing manufacturing, not efficacy; Only supplement an RCT is the honest Pharma & Life Sciences call.
• A safety team sitting on a new disproportionate signal already contained a CRL citing manufacturing, not efficacy before scientific-advice briefing book arrived; no new Clinical and Evidence Strategy path.
• Provenance on scientific-advice briefing book after a CRL citing manufacturing, not efficacy is broken; do not pick RWE can replace or Only supplement an RCT yet.

Analysis required

• Map FDA-response timing and owner in a safety team sitting on a new disproportionate signal.
• Trace CMC, labeling, or pharmacovigilance facts in scientific-advice briefing book after a CRL citing manufacturing, not efficacy.
• Separate an isolated adverse event from a systemic quality issue.
• For this Pharma & Life Sciences Clinical and Evidence Strategy file, read scientific-advice briefing book against a CRL citing manufacturing, not efficacy and write the one fact that would move RWE can replace or for CMC change-control owner.

Recommendation

Choose RWE can replace / Only supplement an RCT on this Pharma & Life Sciences / Clinical and Evidence Strategy packet (scientific-advice briefing book after a CRL citing manufacturing, not efficacy). Lead with the Pharma & Life Sciences option scientific-advice briefing book can support after a CRL citing manufacturing, not efficacy, then the two facts that force it, then the Monday action for CMC change-control owner in a safety team sitting on a new disproportionate signal.